Journal
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volume 107, Issue 3, Pages 758-767Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1742-7843.2010.00573.x
Keywords
-
Categories
Funding
- Osterreichische Forschungsforderungsgesellschaft mbH [DA2005-01-187]
- Austrian Research Promotion Agency [805 419]
Ask authors/readers for more resources
Pyrrolidine dithiocarbamate (PDTC) was examined for its potential in the intranasal treatment of human rhinovirus infections. Prior to clinical testing, a comprehensive non-clinical programme was performed to evaluate the general toxicity of PDTC. The animal experiments included investigations in rodents with study durations ranging from single dose to repeated dosing over a period of 28 days. The routes of administration were intranasal, inhalative, oral and intravenous for single-dose toxicity and pharmacokinetic studies, and intranasal for repeated dose studies. Blood and tissue samples were obtained from PDTC-treated rats to analyse pharmacokinetics and tissue distribution. Accumulation of selected metals due to PDTC treatment was examined in liver, brain, nerves and fat tissues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available